VANCOUVER, BC – Qu Biologics Inc. has published a paper in Nature Publishing Groups’ Scientific Reports focused on its Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s innate immune system.
The peer-reviewed study, in collaboration with Dr. Jeremy Hirota’s laboratory at the University of British Columbia, tested Qu Biologics’ immunotherapy approach to successfully reduce airway immune dysfunction in a mouse model of asthma.
Qu Biologics’ lung targeted SSI, derived from Klebsiella, a bacterial pathogen, was tested in a mouse model of allergic airway disease. Treatment with SSI resulted in a decrease in airway inflammation, with reduction in one of the hallmarks of asthma, the TH2 cytokine response.
The results provide promising support for the potential of Qu Biologics’ SSI technology as a novel treatment for inflammatory lung diseases, including asthma.
The publication, entitled “A novel microbe-based treatment that attenuates the inflammatory profile in a mouse model of allergic airway disease,” was supported by Mitacs, a national, not-for-profit organization that has been building partnerships between academia and industry in Canada for 17 years. It can be viewed online at www.nature.com/articles/srep35338.